Literature DB >> 21656153

Treating prostate cancer in elderly men: how does aging affect the outcome?

Abhay R Shelke1, Supriya G Mohile.   

Abstract

OPINION STATEMENT: Prostate Cancer (PCa) is the second most common cancer in United States and remains the second leading cause of death in the Western world. Because the median age of diagnosis for men with prostate cancer is greater than 75 years, PCa can be considered a disease of the elderly. Several disease-specific factors (e.g., stage, tumor grade, prostate-specific antigen (PSA) level) and patient-specific factors (e.g., age, co-morbidity, and functional status) need to be considered in the decision-making process. In an attempt to incorporate these important factors to select optimal treatment for older individuals, several decision models have been published, yet their utility in clinical practice remains poorly understood. Current guidelines for the management of patients with PCa do not make specific recommendations for the elderly. Clearly there is a need to improve our understanding of the complex interrelationships between old age, co-morbidities, and their impact on expected outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656153     DOI: 10.1007/s11864-011-0160-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  46 in total

Review 1.  Prognostic markers under watchful waiting and radical prostatectomy.

Authors:  Lars Holmberg; Anna Bill-Axelson; Hans Garmo; Juni Palmgren; Bo Johan Norlén; Hans Olov Adami; Jan Erik Johansson
Journal:  Hematol Oncol Clin North Am       Date:  2006-08       Impact factor: 3.722

2.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

3.  Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study.

Authors:  G L Lu-Yao; P Albertsen; J Warren; S L Yao
Journal:  Urology       Date:  1999-08       Impact factor: 2.649

Review 4.  Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.

Authors:  R Paul; J Breul
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

Authors:  C J Tyrrell; A V Kaisary; P Iversen; J B Anderson; L Baert; T Tammela; M Chamberlain; A Webster; G Blackledge
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

Review 8.  Epidemiology of prostate cancer.

Authors:  E David Crawford
Journal:  Urology       Date:  2003-12-22       Impact factor: 2.649

9.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

10.  Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.

Authors:  Tomasz M Beer; William Berry; Emily M Wersinger; Lisa B Bland
Journal:  Clin Prostate Cancer       Date:  2003-12
View more
  10 in total

1.  Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.

Authors:  Matthew R Smith; Dana E Rathkopf; Peter F A Mulders; Joan Carles; Hendrik Van Poppel; Jinhui Li; Thian Kheoh; Thomas W Griffin; Arturo Molina; Charles J Ryan
Journal:  J Urol       Date:  2015-07-04       Impact factor: 7.450

Review 2.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

3.  Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.

Authors:  Wen-Bin Zhu; Ning Xiao; Xing-Jie Liu
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

Review 4.  Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads.

Authors:  Sarah Schroyen; Stéphane Adam; Guy Jerusalem; Pierre Missotten
Journal:  Clin Interv Aging       Date:  2014-12-31       Impact factor: 4.458

5.  Nobiletin suppresses cell viability through AKT pathways in PC-3 and DU-145 prostate cancer cells.

Authors:  Jianchu Chen; Ashley Creed; Allen Y Chen; Haizhi Huang; Zhaoliang Li; Gary O Rankin; Xingqian Ye; Guihua Xu; Yi Charlie Chen
Journal:  BMC Pharmacol Toxicol       Date:  2014-10-24       Impact factor: 2.483

6.  Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.

Authors:  Thomas W Flaig; Ravi C Potluri; Yvette Ng; Mary B Todd; Maneesha Mehra
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

Review 7.  Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.

Authors:  Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

8.  Complete regression of advanced prostate cancer for ten years: A case report and review of the literature.

Authors:  Bing Yan; Xianze Meng; Xiaowei Wang; Pinkang Wei; Zhifeng Qin
Journal:  Oncol Lett       Date:  2013-06-06       Impact factor: 2.967

Review 9.  Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.

Authors:  Gianluigi Taverna; Mauro Seveso; Guido Giusti; Rodolfo Hurle; Pierpaolo Graziotti; Sanja Stifter; Maurizio Chiriva-Internati; Fabio Grizzi
Journal:  Curr Gerontol Geriatr Res       Date:  2014-03-19

Review 10.  Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.

Authors:  Wei Zhang; Teng-Yun Wu; Qi Chen; Xiao-Lei Shi; Guang-An Xiao; Lin Zhao; Chuan-Liang Xu; Tie Zhou; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.